Brokerages Set Mediwound Ltd (MDWD) Price Target at $9.80

Shares of Mediwound Ltd (NASDAQ:MDWD) have received an average rating of “Buy” from the eight analysts that are covering the company, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation and six have given a buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $9.83.

A number of brokerages have issued reports on MDWD. Wells Fargo cut their price target on shares of Mediwound from $9.00 to $8.00 and set an “outperform” rating on the stock in a research note on Tuesday. ValuEngine raised Mediwound from a “strong sell” rating to a “sell” rating in a research report on Saturday, November 25th. Zacks Investment Research downgraded Mediwound from a “buy” rating to a “hold” rating in a research report on Tuesday, November 21st. Finally, Oppenheimer set a $10.00 price objective on Mediwound and gave the stock a “buy” rating in a research report on Friday, December 8th.

How to Become a New Pot Stock Millionaire

Several institutional investors have recently made changes to their positions in MDWD. Renaissance Technologies LLC grew its position in shares of Mediwound by 18.2% during the fourth quarter. Renaissance Technologies LLC now owns 100,600 shares of the biopharmaceutical company’s stock worth $448,000 after buying an additional 15,500 shares in the last quarter. Wells Fargo & Company MN grew its position in shares of Mediwound by 84.6% during the fourth quarter. Wells Fargo & Company MN now owns 101,189 shares of the biopharmaceutical company’s stock worth $450,000 after buying an additional 46,366 shares in the last quarter. Nationwide Fund Advisors acquired a new position in shares of Mediwound during the third quarter worth about $1,538,000. Alyeska Investment Group L.P. acquired a new position in shares of Mediwound during the third quarter worth about $2,140,000. Finally, Meitav Dash Investments Ltd. acquired a new position in shares of Mediwound during the fourth quarter worth about $2,184,000. 32.75% of the stock is owned by institutional investors and hedge funds.

Shares of Mediwound stock traded up $0.05 during trading hours on Friday, reaching $5.45. 86,477 shares of the company’s stock were exchanged, compared to its average volume of 40,765. The stock has a market capitalization of $126.45, a price-to-earnings ratio of -5.56 and a beta of 0.15. Mediwound has a one year low of $3.56 and a one year high of $8.25.

Mediwound (NASDAQ:MDWD) last issued its quarterly earnings results on Monday, March 19th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.16) by $0.08. The company had revenue of $0.53 million for the quarter, compared to analyst estimates of $0.65 million. Mediwound had a negative net margin of 887.38% and a negative return on equity of 286.65%. equities analysts predict that Mediwound will post -0.69 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Brokerages Set Mediwound Ltd (MDWD) Price Target at $9.80” was originally published by Community Financial News and is owned by of Community Financial News. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of international trademark & copyright law. The correct version of this news story can be read at https://www.com-unik.info/2018/03/21/brokerages-set-mediwound-ltd-mdwd-price-target-at-9-80.html.

Mediwound Company Profile

MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.

Analyst Recommendations for Mediwound (NASDAQ:MDWD)

Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit